Keyphrases
Urokinase-type Plasminogen Activator
100%
Camelid Nanobodies
100%
Nanobody
45%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
18%
Nave
18%
Serine Protease
18%
Plasmin
18%
Trypsin-like
18%
Cancer Cells
9%
Tumor Subtype
9%
Metastasis
9%
Adhesion
9%
Low Affinity
9%
Plasminogen
9%
Malignant Tumor
9%
Disease Relapse
9%
Poor Survival
9%
Proteolytic Enzymes
9%
Binder
9%
Survival Prognosis
9%
Pericellular Proteolysis
9%
Pharmacological Tools
9%
Risk Biomarkers
9%
Indirect Competitive Enzyme-linked Immunosorbent Assay (icELISA)
9%
Lead Molecules
9%
Apparent Affinity
9%
Phage Display
9%
Camel
9%
Anticancer Drug Therapy
9%
ELISA Test
9%
Cancer Malignancy
9%
Migration Invasion
9%
Control Process
9%
B-vector
9%
Periplasmic Fraction
9%
Structure-function Relationship
9%
Affinity Binder
9%
Vector System
9%
Single-domain Antibody
9%
Escherichia Coli Expression
9%
Biochemistry, Genetics and Molecular Biology
Urokinase
100%
Single-Domain Antibody
100%
Camelid
100%
Serine Protease
18%
Plasmin
18%
Fibrinolysin
18%
Eicosanoid Receptor
9%
Escherichia coli
9%
Cancer Cell
9%
Anticancer
9%
Protein Catabolism
9%
Peptide Hydrolase
9%
Phage Display
9%
Camel
9%
Information Retrieval
9%
Substrate Concentration
9%